Gary S. Rachelefsky, MD FAAAAI Lectureship: Investing Together in Our Future

The Gary S. Rachelefsky, MD FAAAAI Lectureship: Investing Together in Our Future will be presented by Ruth Tal-Singer, PhD in Presidential Plenary (1601): Digital Health and Remote Patient Monitoring for Patients with Difficult to Control Asthma Convention Center, North Building, Lower Level, Hall 6 on Friday, February 25 at 2:50 pm

Gary S. Rachelefsky, MD FAAAAI

Gary S. Rachelefsky, MD FAAAAI is a graduate of Columbia College and Washington University School of Medicine in St. Louis, Missouri. He completed a medical internship at Bellevue Hospital (NYU); a pediatric residency at Johns Hopkins Hospital (Harriet Lane); a 2-year epidemiology program at the Centers for Disease Control in Atlanta Georgia; and a fellowship in Allergy and Immunology at UCLA.

Dr. Rachelefsky went on to become the Director of the Executive Care Center for Asthma, Allergy and Respiratory Diseases, Professor of Allergy and Immunology, and Associate Director of the Allergy-Immunology Training Program at the David Geffen School of Medicine at UCLA. He was president of the Respiratory and Allergic Disease Foundation and has been a principal investigator of multiple clinical trials. He is the author or co-author of more than 160 peer-reviewed publications dealing with allergy, respiratory disorders and immunology and has personally treated between 80,000 and 100,000 patients in his 40 years in medicine. He is the author of a book (published by McGraw Hill) for parents of children with asthma, “Free Your Child from Asthma: A Four-Week Plan to Eliminate Symptoms.” He was medical director of the Starlight Children’s Foundation’s asthma game for children (Quest for the Code) and is a member of their board of trustees.

Dr. Rachelefsky was president of the American Academy of Allergy, Asthma & Immunology (AAAAI) in 1997, is currently on the editorial board of The Annals of Asthma, Allergy and Immunology, and has been on the editorial boards of the Journal of Allergy & Clinical Immunology, Pediatrics, and Pediatric Allergy and Immunology. He was a member and past President of the American Board of Allergy and Immunology, past chairperson of the allergy and immunology section of the American Academy of Pediatrics (AAP), and is the AAP representative to the National Asthma Education and Prevention Program (National Heart, Lung, and Blood Institute [NHLBI]).

Among his many professional honors, his most cherished include the National Asthma Award for Public Education/Service (NHLBI), the Lay Medical Education Award of the AAP, and twice being recognized for his teaching of house staff and medical students from the Department of Pediatrics, UCLA School of Medicine. Dr. Rachelefsky is now retired, living in Los Angeles with his wife Gail and continues to mentor young medical students. The AAAAI Foundation is pleased to announce the Gary S. Rachelefsky Lectureship, which will foster research in the specialty that has been a lifelong passion for Dr. Rachelefsky. Dr. Rachelefsky's Lectureship was established in 2017.
Ruth Tal-Singer, PhD

Ruth Tal-Singer, PhD, President & Chief Scientific Officer at the COPD Foundation is internationally recognized as an innovative, patient-focused and highly analytical health care leader and clinical scientist with extensive Research and Development experience. She has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. She is adept at building and maintaining partnerships between Pharma, patients, academia and governments. Her wide-ranging technical and scientific knowledge comprises molecular biology, immunology, application of digital technology and in vivo disease models (pre-clinical and clinical). Ruth led the initial clinical development of GSK’s inhaled anti-muscarinic portfolio, currently available to patients as umeclidinium bromide. She has authored 160+ peer-reviewed articles including highly-cited scientific publications (h-index 66). Ruth was the Industry Co-Chair of the COPD Biomarker Qualification Consortium (CBQC) from its inception in 2010 and up to her retirement from GSK in October 2019.

As President & Chief Scientific Officer at the COPD Foundation, Ruth is focused on working with the leadership team, our many partners and the Board on aligning the COPD Foundation strategy with its mission of Research, Community Support, Education and Advocacy.